Direkt zum Inhalt
  1. Publizieren |
  2. Suche |
  3. Browsen |
  4. Neuzugänge rss |
  5. Open Access |
  6. Rechtsfragen |
  7. EnglishCookie löschen - von nun an wird die Spracheinstellung Ihres Browsers verwendet.

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

Lisenko, Katherina ; Dingeldein, G. ; Cremer, Martin ; Kriegsmann, Mark ; Ho, Anthony D. ; Rieger, M. ; Witzens-Harig, Mathias

In: BMC Cancer, 17 (2017), Nr. 359. S. 1-9. ISSN 1471-2407

[thumbnail of 12885_2017_Article_3332.pdf]
Vorschau
PDF, Englisch
Download (699kB) | Lizenz: Creative Commons LizenzvertragAddition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma von Lisenko, Katherina ; Dingeldein, G. ; Cremer, Martin ; Kriegsmann, Mark ; Ho, Anthony D. ; Rieger, M. ; Witzens-Harig, Mathias steht unter einer Creative Commons Namensnennung 3.0 Deutschland

Zitieren von Dokumenten: Bitte verwenden Sie für Zitate nicht die URL in der Adresszeile Ihres Webbrowsers, sondern entweder die angegebene DOI, URN oder die persistente URL, deren langfristige Verfügbarkeit wir garantieren. [mehr ...]

Abstract

Background: The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were obtained in young low risk patients and a reevaluation in an unselected patient cohort is warranted. Methods: In this study, we analyzed 80 PMBCL patients treated with a CHOP-based regimen with and without rituximab. Results: In the non-rituximab cohort 10-year progression free survival (PFS) was 67% and 10-year overall survival (OS) was 72% versus a PFS of 95% and a OS of 92% in the rituximab group, PFS P = 0.001, OS P = 0.023. A subgroup PFS analysis by international prognostic index (IPI) risk revealed that all risk groups benefit from addition of rituximab to induction chemotherapy. In addition, OS probability was higher in the group of non-low risk patients who were treated with rituximab compared to those patients who did not receive rituximab (P = 0.035). In multivariate analysis, only addition of rituximab to induction chemotherapy and reaching complete remission (CR) after first line therapy had a beneficial effect on both PFS and OS, whereas IPI, age, upfront high dose (HD) chemotherapy/autologous blood stem cell transplantation (ABSCT) and rituximab maintenance had no impact on survival. Conclusions: Our data demonstrate a survival benefit in unselected PMBCL patients treated with CHOP-like induction regimen and additional rituximab independently of the IPI risk score.

Dokumententyp: Artikel
Titel der Zeitschrift: BMC Cancer
Band: 17
Nummer: 359
Verlag: BioMed Central; Springer
Ort der Veröffentlichung: London; Berlin; Heidelberg
Erstellungsdatum: 29 Mai 2017 09:17
Erscheinungsjahr: 2017
ISSN: 1471-2407
Seitenbereich: S. 1-9
Institute/Einrichtungen: Medizinische Fakultät Heidelberg und Uniklinikum > Medizinische Universitäts-Klinik und Poliklinik
Medizinische Fakultät Heidelberg und Uniklinikum > Pathologisches Institut
DDC-Sachgruppe: 610 Medizin
Leitlinien | Häufige Fragen | Kontakt | Impressum |
OA-LogoDINI-Zertifikat 2013Logo der Open-Archives-Initiative